• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Safety of Tiotropium in Children with Persistent Asthma

Slideshow

Results of the first study to evaluate use of the adult COPD drug in children age 5 years and younger lay fertile ground for future trials.

Results of the first study to evaluate use of tiotropium as add-on medication to inhaled corticosteroids in children age 5 years and younger found fewer asthma exacerbations vs placebo and similar effects on asthma improvement as placebo. Click through the short slide show above for highlights. Source: Vrijlandt EJLE, El Azzi G, Vandewalker M, et al. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018 Jan 17. pii: S2213-2600(18)30012-2. doi: 10.1016/S2213-2600(18)30012-2.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Albuterol/Budesonide Reduces Risk of Exacerbation in People with Intermittent, Mild-Persistent Asthma

Albuterol/Budesonide Reduces Risk of Exacerbation in People with Intermittent, Mild-Persistent Asthma

Grace Halsey
October 7th 2024
Article

Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes ©Crystal Light/stock.adobe.com

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes

Grace Halsey
May 22nd 2024
Article

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Site Logo

Eternal Springs

Faith T. Fitzgerald, MD
January 13th 2010
Podcast

Doctors, especially primary care doctors, love stories. We love hearing them from patients and telling them to one another. “Anecdotal learning” it’s called by some (somewhat derisively because it’s not science).

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children with Severe Asthma: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children with Severe Asthma: Daily Dose

Sydney Jennings
April 19th 2024
Article

Your daily dose of the clinical news you may have missed.

Tezepelumab for COPD Moves into Phase 3 Planning, Says Amgen / image credit Amgen logo ©MichaelVi/stock.adobe.com

Tezepelumab for COPD Moves into Phase 3 Planning

Grace Halsey
April 17th 2024
Article

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

© 2024 MJH Life Sciences

All rights reserved.